-
Mashup Score: 12
gov: NCT03067844.
Source: pubmed.ncbi.nlm.nih.govCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Supreme Court decision allows alirocumab to stay on US market - 11 month(s) ago
The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market. As Healio previously reported, in 2016 a U.S. District Court jury in Delaware decided that two patents related to monoclonal antibodies for PCSK9 inhibition held by Amgen, which makes
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Supreme Court decision allows alirocumab to stay on US market - 11 month(s) ago
The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market. As Healio previously reported, in 2016 a U.S. District Court jury in Delaware decided that two patents related to monoclonal antibodies for PCSK9 inhibition held by Amgen, which makes
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Supreme Court decision allows alirocumab to stay on US market - 11 month(s) ago
The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market. As Healio previously reported, in 2016 a U.S. District Court jury in Delaware decided that two patents related to monoclonal antibodies for PCSK9 inhibition held by Amgen, which makes
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease - 11 month(s) ago
Background Atherosclerotic cardiovascular disease is the leading cause of death and disability in the Western world. Objective To characterise adults with confirmed coronary heart disease (CHD) and primary heterozygous familial or non-familial hypercholesterolaemia or mixed dyslipidaemia who received alirocumab in a real-world setting. Methods This open, prospective, multicentre,…
Source: Open HeartCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 10Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin - 12 month(s) ago
Alirocumab 300 mg Q4W was generally well tolerated and efficacious for improving lipid levels (e.g., LDL-C and non–HDL-C) in individuals with T2DM receiving max
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 7Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis - 1 year(s) ago
This randomized clinical trial examines the effect of early administration of the PCSK9 inhibitor alirocumab on coronary atherosclerosis using serial multimodality intracoronary imaging in patients with acute myocardial infarction.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
In patients with HeFH, no unexpected long-term safety concerns were observed with alirocumab compared with previously published data; durability of LDL-C-lowering over 3 years (including 1.5 years of parent trials) was demonstrated.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
AbstractAims. To obtain safety and efficacy data of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in a real-life setting in high cardio
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
Purpose During the alirocumab open-label extension study ODYSSEY OLE (open-label extension; NCT01954394), physicians could adjust alirocumab dosing for enrolled patients, who were diagnosed with heterozygous familial hypercholesterolemia (HeFH) and who had completed previous phase III clinical trials with alirocumab. This post hoc analysis evaluated the differences in physician–patient dosing…
Source: SpringerLinkCategories: Cardiologists, Latest HeadlinesTweet
Every week, I have to correct some colleagues who say to pts that #atherosclerosis won’t decrease whereas #REVERSAL and ASTEROID are old studies. #alirocumab on plaque regression. https://t.co/K9YBhOoRT8